United Parcel Service is investing $48 million into 27 temperature-controlled facilities to expand its global cold-chain capabilities for healthcare logistics. The facilities are designed for short-term storage between air and ground transportation and are located across the Americas, Europe, and Asia.

Medications requiring temperature-controlled storage include gene and cell therapies, mRNA vaccines, and GLP-1 injectables. The temperature-sensitive biologics market is valued at $39.1 billion and is projected to grow at an 8.3% compound annual growth rate through 2033. According to the World Health Organization, temperature problems are responsible for 50% of global vaccine waste, costing $35 billion per year.

In January, UPS acquired Frigo-Trans and BPL, European healthcare logistics services companies specializing in cold-chain transportation. In November 2025, UPS acquired Andlauer Healthcare Group for $1.6 billion.

UPS Healthcare President John Bolla said, "These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes." Kate Gutmann, executive vice president and president of international, healthcare and supply chain solutions at UPS, said, "This effort—and all of our work in healthcare logistics—extends from a deep understanding that we're doing more than moving packages. We are helping patients access the medications and treatments they need."

UPS CEO Carol Tomé said, "There have been lots of challenges over the past several years—high inflation, contractions in markets—but healthcare continues to grow." Tomé added, "Our global healthcare portfolio has gained market share every year since 2021. And in the first quarter of this year, we generated our first $3 billion healthcare revenue quarter ever, with all three of our segments delivering year-over-year revenue growth."